Juno

News
Card image cap

Juno bounces back with 'best in class' CAR-T

Juno Therapeutics could be set for a remarkable comeback in CAR-T therapy, after encouraging trial data on a new candidate suggests it could be prove to be the best in class.

News
Card image cap

Juno boosted by CAR-T trial findings in NHL

Juno Therapeutics has been attracting the wrong kind of headlines recently after a series of deaths in a trial of JCAR015, a CAR-T therapy in acute lymphoblastic leukaemia.